COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00403325
Recruitment Status : Completed
First Posted : November 23, 2006
Last Update Posted : November 2, 2008
Genentech, Inc.
Information provided by:
Vitreous -Retina- Macula Consultants of New York

Brief Summary:
The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.

Condition or disease Intervention/treatment Phase
Central Serous Chorioretinopathy Drug: rhuFab V2 [ranibizumab] ( Lucentis ) Phase 1

Detailed Description:
This is an open-label, Phase I study of intravitreally administered ranibizumab in subjects with unresolving CSC and subfoveal fluid. Patients will be evaluated at baseline with ophthalmic examination, fluorescein angiography, optical coherence tomography, and color photography. Subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered every 28 days (± 2 days) for 3 injections. Thereafter they are to be evaluated every month until month 12. Treatment will be administered to patients if there is presence of active leakage as determined by fluorescein angiography or persistence presence of sub retinal fluid upon OCT examination at that monthly visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid.
Study Start Date : August 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Primary Outcome Measures :
  1. To determine the safety and tolerability of 0.5 mg dose of Ranibizumab in the treatment of chronic central serous retinopathy (CSC)

Secondary Outcome Measures :
  1. Mean change in VA compared to baseline at month 6 and month 12
  2. Proportion of patients with 20/20 vision at month 6 and 12 as compared to baseline
  3. Proportion of patients losing ≤ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 6 and 12
  4. Proportion of patients gaining ≥ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 6 and 12
  5. Change in subretinal fluid (as measured by optical coherence tomography) from baseline at month 3, 6, 9 and 12

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • A history of persistent central serous chorioretinopathy present for at least 3 months Best-corrected visual acuity (BCVA) of 20/40 (73 letters on the ETDRS chart) to light perception as measured by ETDRS protocol refraction.
  • No signs of choroidal neovascularization
  • Documented subfoveal fluid by OCT
  • Active leak associated with the subfoveal fluid
  • The ability and willingness to provide written informed consent

Exclusion Criteria:

  • Prior treatment with laser or PDT
  • Have uncontrolled hypertension
  • Have a history of thromboembolic events including stroke, transient ischemic attacks, and myocardial infarction
  • Have use of or need for continued anticoagulation therapy, except aspirin 325 mg/day.
  • Are receiving or require chronic concomitant therapy with systemic (> 5 mg) or topical ocular corticosteroids. Chronic concomitant therapy is defined as multiple doses taken daily for 14 or more consecutive days at any time within 6 months prior to screening
  • Previously vitrectomized eyes.
  • Had allergic reactions to fluorescein dye or lack of venous access.
  • Any other additional ocular diseases which could irreversibly compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy (AION), age related macular degeneration (AMD), retinal detachment, severe cataracts, etc.
  • An anticipated need for ocular surgery during the duration of the trial.
  • Within 1 month prior to screening, have had intra ocular surgeries (including cataract surgery) in the study eye.
  • Intravitreal triamcinolone or bevacizumab in the previous 2 months
  • Uncontrolled glaucoma (IOP > 24 mmHg) on greater than 3 medications.
  • Within 1 month prior to screening had YAG laser capsulotomy in the study eye
  • Have received any other systemic experimental drug within 12 weeks prior to enrollment.
  • Rubeosis iridis or neovascular glaucoma
  • Any untreated rhegmatogenous retinal detachment.
  • A visual acuity of worse than 20/400 in the fellow eye.
  • Unwilling or unable to follow or comply with all study related procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00403325

Layout table for location information
United States, New York
Vitreous Retina Macula Consultants of New York, P.C.
New York, New York, United States, 10022
Sponsors and Collaborators
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Richard F. Spaide, M.D. Vitreous Retina Macula Consultants of New York, P.C.
Layout table for additonal information
Responsible Party: Richard Spaide, MD / Principal Investigator, Vitreous Retina Macula Consultants of New York Identifier: NCT00403325    
Other Study ID Numbers: FVF3850S
First Posted: November 23, 2006    Key Record Dates
Last Update Posted: November 2, 2008
Last Verified: October 2008
Keywords provided by Vitreous -Retina- Macula Consultants of New York:
Central Serous Chorioretinopathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents